NCT04897243

Antiretroviral Speed Access Program

A Prospective Cohort Study Examining Two Models of Care for B/F/TAF Initiation in HIV-infected, ART-naïve Newly Referred Patients
Dr. Bertrand Lebouche·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
HIV Infection
Drug/Device/Intervention
Biktarvy
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Dr. Bertrand Lebouche
Funder
McGill University Health Centre/Research Institute of the McGill University Health Centre
Location
Montréal, Canada
Timeline & enrollment
Phase
N/A
Start date
Jan 29, 2020
End date
Dec 01, 2022
Enrollment
75 participants
Primary outcome

Change in perceived problem solving,Change in perceived provider empathy,Change in treatment satisfaction,Perceived unmet healthcare needs

Summary

Migrant populations represent an increasing proportion of newly referred people living with
 HIV in Canada, particularly in Quebec. Timely HIV care of newly referred patients has
 important individual-level health benefits that can result in decreased transmission and
 benefit the society as a whole. Yet, the timing of events in the HIV care cascade (from
 linkage to care to sustained viral suppression) together with the specific experience of care
 of these vulnerable populations (asylum-seekers, international students, patients with no
 status) who often face specific psycho-social and/or financial issues, has rarely been
 studied. In particular, little is known about their experience of HIV care whether they are
 referred to a multidisciplinary clinic or a physician-only clinic.
 
 In a context where B/F/TAF will be provided free-of-charge to all enrolled participants
 including migrant populations, we aim to investigate what model of care can best address
 current deficiencies in the standard HIV care cascade for newly-referred patients, which
 often involves delays in linkage to care and starting ART.

ICD-10 classifications
HIV disease resulting in other viral infectionsHuman immunodeficiency virus [HIV] diseaseHIV disease resulting in other bacterial infectionsAcute HIV infection syndromeUnspecified human immunodeficiency virus [HIV] disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04897243
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04897243 through Pure Global AI's free database. This phase not specified trial is sponsored by Dr. Bertrand Lebouche and is currently Recruiting. The study focuses on HIV Infection. Target enrollment is 75 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.